‘There is no reality here’: Researchers whose work inspired a startup to charge $8,000 to fill patients’ veins with young blood say it’s putting lives at risk
A startup called Ambrosia Medical that charges $8,000 to fill your veins with the blood of young people plans to launch its first clinic in New York City at the end of this year.
Researchers who study blood transfusions called the procedure “dangerous” and said the idea behind it is based on “incorrect interpretations” of their work.
Founded by Stanford graduate Jesse Karmazin, the company recently completed the first clinical trial designed to assess the benefits of young blood transfusions. Those results have not been published.
Does young blood hold the keys to a long and healthy life? Startup founder and and Stanford Medical graduate Jesse Karmazin believes it might, so he launched a startup called Ambrosia Medical that fills older people’s veins with fresh blood from young donors.
But researchers who study the procedure say it poses major risks for patients, including an elevated risk of developing several serious conditions later in life, such as graft-versus-host disease, which can occur when transfused blood cells attack the patient’s own cells, and transfusion-associated lung injury.
Irina and Michael Conboy, two University of California at Berkeley researchers who’ve published research on young blood transfusions in mice, called Ambrosia’s plans “dangerous.”
“They quite likely could inflict bodily harm,” Irina Conboy told Business Insider.
The Conboys’ concern stems from an awareness of what happens in the body when it receives foreign blood from a donor.
“It is well known in the medical community — and this is also the reason we don’t do transfusions frequently — that in 50% of patients there are very bad side effects. You are being infused with somebody else’s blood and it doesn’t match,” Conboy said. “That unleashes a strong immune reaction.”
Karmazin told Business Insider that the Conboys’ statements “are not supported by data or clinical experience.”
“Millions of plasma transfusions are performed …read more
Source:: Business Insider